Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update

Core Viewpoint - Rakovina Therapeutics Inc. reported its financial results for Q2 2025, highlighting advancements in AI-powered drug discovery for cancer therapies and recent corporate developments [1]. Financial Highlights - Cash and cash equivalents as of June 30, 2025, were CAD 1.88 million, an increase from CAD 1.31 million as of December 31, 2024 [5]. - Working capital improved to CAD 622,851 from CAD 321,442 [5]. - Total assets increased to CAD 6.55 million from CAD 6.24 million [5]. - Total liabilities rose significantly to CAD 3.34 million from CAD 1.94 million [5]. - The net loss for Q2 2025 was CAD 2.92 million, compared to a loss of CAD 820,720 in Q2 2024 [8]. Research and Development Expenses - R&D expenses for Q2 2025 were CAD 1.61 million, a substantial increase from CAD 479,785 in Q2 2024 [8]. - General and administrative expenses were CAD 1.21 million, up from CAD 276,183 [8]. Corporate Developments - The company closed a non-brokered private placement on June 6, 2025, raising approximately CAD 3.56 million [7]. - A reverse share consolidation was implemented on June 24, 2025, at a ratio of 1-for-10, resulting in 21,148,039 common shares outstanding as of June 30, 2025 [7]. - On June 30, 2025, the company announced intentions to amend certain outstanding warrants and convertible debentures totaling CAD 1.45 million, pending TSXV approval [7]. - A warrant exercise incentive program was announced on July 24, 2025, to encourage early exercise of certain outstanding warrants [7]. Stock Options - The company granted 540,000 stock options post-consolidation to various stakeholders, exercisable at CAD 0.70 per share with a vesting period of six months over three years [7].